Navigation Links
U.S. FDA Approves First and Only Oral Contraceptive Demonstrated to Treat Heavy Menstrual Bleeding (HMB)
Date:3/14/2012

WAYNE, N.J., March 14, 2012 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Natazia® (estradiol valerate and estradiol valerate/dienogest) tablets for the treatment of heavy menstrual bleeding (HMB) that is not caused by any diagnosed conditions of the uterus (womb), in women who choose an oral contraceptive (OC) for contraception.  With this approval, Natazia is the first and only oral contraceptive indicated for the treatment of HMB.

Natazia was approved in May 2010 for the prevention of pregnancy.  The contraceptive efficacy of Natazia has not been evaluated in women with a body mass index (BMI) greater than 30 kg/m2.

"Heavy menstrual bleeding is a common disorder reported by around three million women of reproductive age each year in the United States[1]," said Pamela A. Cyrus, M.D., Vice President and Head of U.S. Medical Affairs, Bayer HealthCare Pharmaceuticals.  "As the first oral contraceptive treatment approved for heavy menstrual bleeding in women without organic pathology who choose an OC for contraception, Natazia represents a new treatment approach for appropriate women with this medical condition."

Recognized signs of HMB may include menstrual flow that soaks through one or more sanitary pads or tampons every hour, the need to use double sanitary protection to control heavy flow, or the need to wake up to change sanitary protection during the night.[2]

About the HMB Clinical Program for Natazia

The approval of Natazia for this HMB indication was based on two identically-designed, multicenter, double-blind, randomized, placebo controlled trials – one in North America and one in Europe and Australia.  The studies included a total of 421 women, who were 18 years of age or older, with a diagnosis of dysfunctional uterine bleeding characterized as heavy,
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Additional Manufacturer of Methoxsalen
2. FDA Approves New Skin Cancer Drug First Tested in Arizona by Scottsdale Healthcare and TGen
3. FDA approves Novartis drug Gleevec® label recommending extending treatment to three years for certain GIST patients after surgery
4. FDA Approves Gleevec For Expanded Use in Patients With Rare Gastrointestinal Cancer
5. FDA Approves Kalydeco to Treat Rare Form of Cystic Fibrosis
6. ASAM Approves Prescription Drug Policy
7. FDA Approves Picato® (ingenol mebutate) Gel, the First and Only Topical Actinic Keratosis (AK) Therapy With 2 or 3 Consecutive Days of Once-Daily Dosing
8. FDA Approves Shared REMS (Risk Evaluation and Mitigation Strategy) Program for all TIRF (Transmucosal Immediate Release Fentanyl) Pain Treatments
9. FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension
10. FDA Approves Mechanical Cardiac Assist Device for Children With Heart Failure
11. FDA Approves Hologics Cervista High Throughput Automation System for Cervical Cancer Screening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Global Markets ... -- Focus on End Users ... A drug delivery system is ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... FRAMINGHAM, Mass. , Jan. 14, 2014 ... a leading innovator of less invasive, miniaturized circulatory support ... failure, today announced that it expects revenues for the ... bringing expected full-year 2013 revenues to approximately $208 million. ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... 2011 Reportlinker.com announces that a ... in its catalogue: ... Alternatives to Needle-Based Systems for Vaccine ... http://www.reportlinker.com/p0590267/Needle-Free-Drug-Delivery-The-Market-for-Alternatives-to-Needle-Based-Systems-for-Vaccine-and-Biologics.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology The line ...
... WOONSOCKET, R.I., Aug. 16, 2011 Medicare Part D ... to pay 100 percent of previously subsidized prescription costs, ... they are to switch to more affordable or generic ... Medicine concludes. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) ...
Cached Medicine Technology:Needle-Free Drug Delivery: The Market for Alternatives to Needle-Based Systems for Vaccine and Biologics 2Needle-Free Drug Delivery: The Market for Alternatives to Needle-Based Systems for Vaccine and Biologics 3Needle-Free Drug Delivery: The Market for Alternatives to Needle-Based Systems for Vaccine and Biologics 4Needle-Free Drug Delivery: The Market for Alternatives to Needle-Based Systems for Vaccine and Biologics 5CVS Caremark, Harvard and Brigham and Women's Researchers Say Medicare 'Donut Hole' Can Lead to a Decrease in Medication Adherence 2CVS Caremark, Harvard and Brigham and Women's Researchers Say Medicare 'Donut Hole' Can Lead to a Decrease in Medication Adherence 3
(Date:7/10/2014)... The benefits of medical imaging far outweigh the ... Right Way, with The Right Radiation Dose. However, overuse ... Mayo Clinic is leading a collaborative effort to ensure ... published online in the Journal of Patient Safety ... Joint Commission, the Intersociety Accreditation Commission, and the Centers ...
(Date:7/10/2014)... For decades, health-conscious people around the globe have ... figuring this was one of the paths to good ... clinical trials of antioxidant supplements have repeatedly dashed the ... their cancer risk. Virtually all such trials have ... In fact, in several trials antioxidant supplementation has been ...
(Date:7/10/2014)... Men who experience hot flashes are unlikely to ... from their silent suffering if they are willing ... a Baylor University case study., After seven weeks of ... hot flashes following prostate cancer surgery showed a drastic ... impressive improvement in sleep quality, according to the study., ...
(Date:7/9/2014)... MA -- Vasectomy was associated with a small increased ... advanced or lethal prostate cancer according to a new ... researchers found that the association remained even among men ... of lethal cancer cannot be explained by diagnostic bias. ... date to look at the link between vasectomy and ...
(Date:7/9/2014)... cancer, researchers have uncovered mutations in a cell-signaling pathway ... knowledge may expand treatments for patients because drugs targeting ... are in clinical trials. , Reporting July 9 in ... (TCGA), including researchers at Washington University School of Medicine ... studied tumors from 230 patients with lung adenocarcinoma. , ...
Breaking Medicine News(10 mins):Health News:Mayo Clinic calls for standardization of safe imaging protocols for children 2Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Vasectomy may increase risk of aggressive prostate cancer 2Health News:Lung cancer study hints at new treatments 2
... CHICAGO, June 24 Bally Total Fitness Holding,Corporation today ... its Chief Executive Officer, effective July 1. Mr. Sheehan ... Directors., Mr. Sheehan, age 46, served as the ... serving as Chief Operating Officer, Mr. Sheehan,served as Executive ...
... control symptoms better, studies show , , TUESDAY, June 24 ... delivery system for an older drug appear to hold ... In the first study, patients taking the drug SLV308 ... tremors and slowness of movement. The results also indicate ...
... announced today Reproductive Health Matters , May 2008 ... Promoting Sexual and Reproductive rights". Under conditions of global ... growing numbers of refugees and internally displaced persons (IDPs) ... right to have rights,. By the end of ...
... Devices known as brain-machine interfaces could someday be ... prosthetic limbs with just their thoughts. Now, University of ... devising a way for computerized devices not only to ... with the brain as it learns. , Instead of ...
... but doing little to ... within the facility, CHICAGO, June 24 The American ... survey asking 1,000 women,their opinions on medical spas. Findings revealed ... customers of these facilities.,Yet half of those women are compromising ...
... The Rehabilitation Institute,of Chicago and MediCom Worldwide, Inc. ... July 18th and 19th. The meeting will be ... University in Chicago., This year, the conference ... scientific agenda will focus on the latest information,issues, ...
Cached Medicine News:Health News:Bally Total Fitness Announces New Chief Executive Officer 2Health News:New Hope for Parkinson's Patients 2Health News:May 2008 issue on conflict and crisis settings: Promoting sexual and reproductive rights 2Health News:Researchers develop neural implant that learns with the brain 2Health News:Researchers develop neural implant that learns with the brain 3Health News:Millennials' Medspa Influence 2Health News:3rd Annual Conference on Pain Jointly Sponsored By Rehabilitation Institute of Chicago and MediCom Worldwide, Inc. 2
Ethicon, medium clip size, 10mm, rotatable take apart...
Solid phase capture sandwich ELISA assay using a microwell format....
The C-Reactive Protein (CRP) assay is used for the quantitative analysis of C-reactive protein in human serum and plasma. Kit is for use with the Abbot Laboratories Aeroset, ARCHITECT c8000 or ARCHI...
... broad menu clinical chemistry analyzer designed for ... Care givers can now perform routine multi-chemistry ... minute of hands-on time. Complete panel results ... expensive laboratory analyzers are available in under ...
Medicine Products: